Abeona Therapeutics reported steady launch-year commercial execution for its flagship cell-based gene therapy, Zevaskyn (prademagene zamikeracel), highlighting treatment progress across expanded Qualified Treatment Centers. Additionally, the company secured New Technology Add-On Payment (NTAP) status from the Centers for Medicare & Medicaid Services, providing supplemental hospital reimbursement pathways to facilitate broader patient access.